Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP lifted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 58.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 293,200 shares of the company's stock after acquiring an additional 108,600 shares during the quarter. Two Sigma Advisers LP owned 0.35% of Verve Therapeutics worth $1,654,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc lifted its holdings in shares of Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after buying an additional 8,237 shares during the period. BNP Paribas Financial Markets purchased a new stake in Verve Therapeutics during the fourth quarter worth $50,000. KLP Kapitalforvaltning AS acquired a new stake in Verve Therapeutics during the fourth quarter valued at $101,000. China Universal Asset Management Co. Ltd. grew its position in Verve Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock valued at $101,000 after buying an additional 1,676 shares during the period. Finally, Arizona State Retirement System increased its holdings in Verve Therapeutics by 15.8% in the fourth quarter. Arizona State Retirement System now owns 19,593 shares of the company's stock valued at $111,000 after buying an additional 2,669 shares in the last quarter. Hedge funds and other institutional investors own 97.11% of the company's stock.

Verve Therapeutics Price Performance

NASDAQ VERV traded down $0.17 during trading hours on Friday, hitting $4.43. 3,010,738 shares of the company's stock traded hands, compared to its average volume of 1,894,191. The company has a market capitalization of $394.90 million, a PE ratio of -1.80 and a beta of 1.82. Verve Therapeutics, Inc. has a 52-week low of $2.86 and a 52-week high of $9.31. The firm's 50-day moving average is $4.48 and its 200-day moving average is $5.74.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business had revenue of $32.98 million during the quarter, compared to analyst estimates of $7.13 million. Equities research analysts predict that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on VERV shares. William Blair reissued an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Royal Bank of Canada reduced their price target on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Wall Street Zen raised Verve Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright increased their target price on Verve Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a research report on Monday, April 14th. Finally, Guggenheim boosted their target price on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $25.75.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.